Algernon Pharmaceuticals (CSE: AGN)'s most advanced drug Ifenprodil for Idiopathic Pulmonary Fibrosis and chronic cough will have its full Phase 2a study data set released in the upcoming days.
One other publicly traded company has a drug in Phase 2 trials for Idiopathic Pulmonary Fibrosis and chronic cough called Trevi Therapeutics, Inc. (TRVI).
Prior to TRVI releasing the Phase 2 study data for its IPF/chronic cough drug on February 24th, TRVI was trading for $0.46 per share. Within one week of the data being released, TRVI rallied by 245.65% to a March 2nd high of $1.59 per share. Today, TRVI is trading for $3.68 per share with a market cap of US$157.4 million.
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from AGN of US$100,000 cash for a twelve-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.